SXTC 📈 China SXT Pharmaceuticals - Overview
Exchange: NASDAQ • Country: China • Currency: USD • Type: Common Stock • ISIN: VGG2161P1320
SXTC: Medicines, Herbs, Pharmaceuticals, Drugs, Supplements, Remedies, Treatments
China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers advanced, fine, and regular TCMP products, and raw medicinal material, such as SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, ShaRen, and ChenXiang. It provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. The company had an end-customer base of pharmaceutical companies, chain pharmacies, and hospitals, as well as pharmaceutical distributors. China SXT Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Taizhou, China. Web URL: https://www.sxtchina.com
Additional Sources for SXTC Stock
News:
Wall Street Journal
Benzinga
Yahoo Finance
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
SXTC Stock Overview
| Market Cap in USD | 2m |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| GiC Sub-Industry | Personal Care Products |
| IPO / Inception | 2019-01-04 |
SXTC Stock Ratings
| Growth 5y | -96.1% |
| Fundamental | -34.7% |
| Dividend | - |
| Rel. Strength Industry | -708 |
| Analysts | - |
| Fair Price Momentum | 0.17 USD |
| Fair Price DCF | - |
SXTC Dividends
No Dividends PaidSXTC Growth Ratios
| Growth Correlation 3m | -90.7% |
| Growth Correlation 12m | -94.2% |
| Growth Correlation 5y | -89.8% |
| CAGR 5y | -66.26% |
| CAGR/Mean DD 5y | -0.79 |
| Sharpe Ratio 12m | -0.61 |
| Alpha | -79.70 |
| Beta | -0.36 |
| Volatility | 165.73% |
| Current Volume | 326.9k |
| Average Volume 20d | 1643.1k |
What is the price of SXTC stocks?
As of December 22, 2024, the stock is trading at USD 0.32 with a total of 326,861 shares traded.
Over the past week, the price has changed by -15.61%, over one month by -12.35%, over three months by -47.76% and over the past year by -82.38%.
As of December 22, 2024, the stock is trading at USD 0.32 with a total of 326,861 shares traded.
Over the past week, the price has changed by -15.61%, over one month by -12.35%, over three months by -47.76% and over the past year by -82.38%.
Is China SXT Pharmaceuticals a good stock to buy?
Probably not. Based on ValueRay Fundamental Analyses, China SXT Pharmaceuticals (NASDAQ:SXTC) is currently (December 2024) not a good stock to buy. It has a ValueRay Fundamental Rating of -34.65 and therefor a somewhat negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of SXTC as of December 2024 is 0.17. This means that SXTC is currently overvalued and has a potential downside of -46.88%.
Probably not. Based on ValueRay Fundamental Analyses, China SXT Pharmaceuticals (NASDAQ:SXTC) is currently (December 2024) not a good stock to buy. It has a ValueRay Fundamental Rating of -34.65 and therefor a somewhat negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of SXTC as of December 2024 is 0.17. This means that SXTC is currently overvalued and has a potential downside of -46.88%.
Is SXTC a buy, sell or hold?
China SXT Pharmaceuticals has no consensus analysts rating.
China SXT Pharmaceuticals has no consensus analysts rating.
What are the forecast for SXTC stock price target?
According to ValueRays Forecast Model, SXTC China SXT Pharmaceuticals will be worth about 0.2 in December 2025. The stock is currently trading at 0.32. This means that the stock has a potential downside of -43.75%.
According to ValueRays Forecast Model, SXTC China SXT Pharmaceuticals will be worth about 0.2 in December 2025. The stock is currently trading at 0.32. This means that the stock has a potential downside of -43.75%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 0.2 | -43.8% |